Cholecalciferol in Treating Patients With Myelodysplastic Syndrome
RATIONALE: Cholecalciferol (vitamin D) may improve quality of life by increasing blood counts, decreasing fatigue, and improving other symptoms of myelodysplastic syndrome.
PURPOSE: This phase II trial is studying how well cholecalciferol works in treating patients with myelodysplastic syndrome.
Dietary Supplement: cholecalciferol
|Study Design:||Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Orthomolecular Vitamin D3 in Low-Risk Myelodysplastic Syndrome: An Open-Label Clinical Trial|
|Study Start Date:||July 2003|
|Study Completion Date:||September 2006|
|Primary Completion Date:||June 2005 (Final data collection date for primary outcome measure)|
- Determine the efficacy of cholecalciferol, in terms of hematological improvement, in patients with low- or intermediate-risk myelodysplastic syndromes.
- Determine the effect of this drug on disease symptoms, fatigue, and the overall health-related quality of life of these patients.
OUTLINE: This is an open-label, pilot study.
Patients receive oral cholecalciferol once daily. Treatment continues for 6 months in the absence of disease progression or unacceptable toxicity.
PROJECTED ACCRUAL: A total of 36 patients will be accrued for this study.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00068276
|United States, North Carolina|
|Comprehensive Cancer Center at Wake Forest University|
|Winston-Salem, North Carolina, United States, 27157-1082|
|Study Chair:||Istvan Molnar, MD||Comprehensive Cancer Center of Wake Forest University|
|OverallOfficial:||Bayard L. Powell, MD||Comprehensive Cancer Center of Wake Forest University|